ArticleFrontiers in oncology2024
Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Quantifying the Interplay Between PRAME Expression and Classical Morphology: A Multivariable Analysis of 954 Suspected Melanocytic Lesions.Dermatopathology (Basel, Switzerland) · 2026Article
- In Vivo Visualization and Quantification of Dermal Nevus Microvasculature Using Super-Resolution Ultrasound of Erythrocytes.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Article
- Cutaneous Melanoma Care in Low-Resource Settings: Surgical Disparities in Global Reconstructive Oncology.Plastic and reconstructive surgery. Global open · 2026Article
- Cutaneous melanoma in Kazakhstan: epidemiological trends and economic burden on the healthcare system.Archives of public health = Archives belges de sante publique · 2026Article
- The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.Frontiers in immunology · 2026Article
- Global Burden and Drivers of Cutaneous Malignant Melanoma Among Women Aged 55 and Older.International journal of women's health · 2026Article
- The impact of prevalent primary cancers in melanoma patients on survival.Frontiers in oncology · 2026Article
- Combination of SH003 and paclitaxel modulates tumor microenvironment and inhibits metastasis of metastatic melanoma.Medical oncology (Northwood, London, England) · 2025Article
- Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.BMC cancer · 2025Article
- Global Burden and Trends of Cutaneous Malignant Melanoma in the Elderly Population: Analysis of Global Burden of Disease Study 2021.Clinical, cosmetic and investigational dermatology · 2025Article
- Mitochondrial dysfunction and apoptotic signaling induced by the combined action of 2-aminoethyl dihydrogen phosphate and methyl-β-cyclodextrin in melanoma cells.Frontiers in pharmacology · 2025Article
- Global burden of hypertensive heart disease attributable to high body mass index from 1990 to 2021: a multidimensional analysis and public health response.Frontiers in cardiovascular medicine · 2025Article
- Single-cell and machine learning integration reveals ferroptosis-driven immune landscapes for melanoma stratification.Frontiers in immunology · 2025Article
- The microbiome as a therapeutic co-driver in melanoma immuno-oncology.Frontiers in medicine · 2025Review
- Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy.Oncology research · 2025Review
- Global, regional, and national burden of premenopausal and postmenopausal malignant melanoma from 1990 to 2021: a comprehensive cross-sectional analysis.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous Malignant Melanoma (CMM) is a significant global health challenge. Understanding regional differences in CMM prevalence and trends is crucial for developing targeted strategies. To address this, we analyzed epidemiological patterns and investigated risk factors for CMM-related mortality. Methods: This study analyzed CMM using data from the 2021 Global Burden of Diseases survey, covering 204 countries and territories. We evaluated the number and age-standardized rates of prevalence (ASPR), mortality (ASMR), disability-adjusted life years (ASDR), and annual percentage changes (EAPCs). Trends were stratified by region, country, age, sex, and Sociodemographic Index (SDI). A Bayesian Age-Period-Cohort model projected future prevalence, mortality, and DALYs, while decomposition analysis identified key drivers of CMM burden. Frontier analysis further associated CMM outcomes with socio-demographic development. Results: In 2021, the global prevalence of CMM reached 833,215 cases, a 161.3% increase since 1990. During this period, the ASPR rose from 19.13 to 25.37 per 100,000, while the ASMR declined from 0.84 to 0.73 per 100,000. DALYs increased by 60.5%, from 1,045,777 to 1,678,836. The high SDI region had the highest ASPR, ASMR, and ASDR. Decomposition analysis identified population growth, demographic aging, and epidemiological changes as equal drivers of CMM DALYs globally. Countries like New Zealand and Australia demonstrated the most significant effective differences, indicating potential for improvement in CMM management. By 2045, the global ASPR is projected to rise to 36.61, with ASMR and ASDR expected to decrease to 0.79 and 10.21 per 100,000. Conclusion: CMM poses an increasing global health concern, with ASPR steadily rising. While this analysis shows a decline in global ASMR and ASDR overall, these rates are actually increasing in low SDI regions, and projections indicate that this trend will likely continue until 2045.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.